FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289912917> ?p ?o ?g. }

• W4289912917 endingPage "1992" @default.
• W4289912917 startingPage "1983" @default.
• W4289912917 abstract "Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant morbidity and mortality. Although critical for disease control, there is no consensus for the best immunosuppressive regimen. Most authors use steroids first line, followed by other agents for steroid failures. Upfront combined regimens offer the advantage of reduced steroid exposure and toxicity as well as increased efficacy. We retrospectively analyzed data from 32 patients with AHA treated on an identical such institutional protocol: cyclophosphamide 1000 mg on days 1 and 22, dexamethasone 40 mg on days 1, 8, 15, and 22, and rituximab 100 mg on days 1, 8, 15, and 22 (the regimen was termed CyDRi). All patients received at least 1 cycle of CyDRi. If necessary, CyDRi was repeated until remission, no sooner than day 43 of the previous cycle. Bleeding control was rapidly achieved. The median time for bleeding control was 15.5 days (range, 0-429 days; interquartile range, 2.5-29.5 days). Thirty-one (96.8%) of 32 patients achieved durable complete remission (CR); 29 (90.6%) of 32 patients were alive at last follow-up, all of them in CR. The median time to reach first CR was 77 days (range, 19-939 days; interquartile range, 31-115 days). Toxicity and side effects were acceptable and milder than those of commonly used, prolonged steroid therapies. In conclusion, the CyDRi regimen produced markedly higher CR rates and overall survival than currently used sequential regimens. Taken together, CyDRi proved to be an attractive option for the immunosuppression of elderly patients with AHA." @default.
• W4289912917 created "2022-08-06" @default.
• W4289912917 creator A5000520938 @default.
• W4289912917 creator A5002498728 @default.
• W4289912917 creator A5017110693 @default.
• W4289912917 creator A5025218236 @default.
• W4289912917 creator A5028748951 @default.
• W4289912917 creator A5042053195 @default.
• W4289912917 creator A5047340010 @default.
• W4289912917 creator A5049129485 @default.
• W4289912917 creator A5049681466 @default.
• W4289912917 creator A5067418606 @default.
• W4289912917 creator A5074402016 @default.
• W4289912917 creator A5075279096 @default.
• W4289912917 creator A5080861242 @default.
• W4289912917 date "2022-11-03" @default.
• W4289912917 modified "2023-10-17" @default.
• W4289912917 title "Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen" @default.
• W4289912917 cites W14127768 @default.
• W4289912917 cites W1792313494 @default.
• W4289912917 cites W1964074649 @default.
• W4289912917 cites W1967479627 @default.
• W4289912917 cites W1996499278 @default.
• W4289912917 cites W2001205289 @default.
• W4289912917 cites W2010561398 @default.
• W4289912917 cites W2021075966 @default.
• W4289912917 cites W2041426282 @default.
• W4289912917 cites W2059259955 @default.
• W4289912917 cites W2108177522 @default.
• W4289912917 cites W2149564822 @default.
• W4289912917 cites W2157045826 @default.
• W4289912917 cites W2314428654 @default.
• W4289912917 cites W2611005000 @default.
• W4289912917 cites W2965876256 @default.
• W4289912917 cites W2972821068 @default.
• W4289912917 cites W3021433538 @default.
• W4289912917 cites W3112315877 @default.
• W4289912917 cites W3200089888 @default.
• W4289912917 doi "https://doi.org/10.1182/blood.2022016873" @default.
• W4289912917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35930747" @default.
• W4289912917 hasPublicationYear "2022" @default.
• W4289912917 type Work @default.
• W4289912917 citedByCount "5" @default.
• W4289912917 countsByYear W42899129172022 @default.
• W4289912917 countsByYear W42899129172023 @default.
• W4289912917 crossrefType "journal-article" @default.
• W4289912917 hasAuthorship W4289912917A5000520938 @default.
• W4289912917 hasAuthorship W4289912917A5002498728 @default.
• W4289912917 hasAuthorship W4289912917A5017110693 @default.
• W4289912917 hasAuthorship W4289912917A5025218236 @default.
• W4289912917 hasAuthorship W4289912917A5028748951 @default.
• W4289912917 hasAuthorship W4289912917A5042053195 @default.
• W4289912917 hasAuthorship W4289912917A5047340010 @default.
• W4289912917 hasAuthorship W4289912917A5049129485 @default.
• W4289912917 hasAuthorship W4289912917A5049681466 @default.
• W4289912917 hasAuthorship W4289912917A5067418606 @default.
• W4289912917 hasAuthorship W4289912917A5074402016 @default.
• W4289912917 hasAuthorship W4289912917A5075279096 @default.
• W4289912917 hasAuthorship W4289912917A5080861242 @default.
• W4289912917 hasBestOaLocation W42899129171 @default.
• W4289912917 hasConcept C119060515 @default.
• W4289912917 hasConcept C126322002 @default.
• W4289912917 hasConcept C141071460 @default.
• W4289912917 hasConcept C2776694085 @default.
• W4289912917 hasConcept C2776755627 @default.
• W4289912917 hasConcept C2779338263 @default.
• W4289912917 hasConcept C2780252810 @default.
• W4289912917 hasConcept C2780401358 @default.
• W4289912917 hasConcept C2780653079 @default.
• W4289912917 hasConcept C2781413609 @default.
• W4289912917 hasConcept C29730261 @default.
• W4289912917 hasConcept C71924100 @default.
• W4289912917 hasConcept C90924648 @default.
• W4289912917 hasConceptScore W4289912917C119060515 @default.
• W4289912917 hasConceptScore W4289912917C126322002 @default.
• W4289912917 hasConceptScore W4289912917C141071460 @default.
• W4289912917 hasConceptScore W4289912917C2776694085 @default.
• W4289912917 hasConceptScore W4289912917C2776755627 @default.
• W4289912917 hasConceptScore W4289912917C2779338263 @default.
• W4289912917 hasConceptScore W4289912917C2780252810 @default.
• W4289912917 hasConceptScore W4289912917C2780401358 @default.
• W4289912917 hasConceptScore W4289912917C2780653079 @default.
• W4289912917 hasConceptScore W4289912917C2781413609 @default.
• W4289912917 hasConceptScore W4289912917C29730261 @default.
• W4289912917 hasConceptScore W4289912917C71924100 @default.
• W4289912917 hasConceptScore W4289912917C90924648 @default.
• W4289912917 hasIssue "18" @default.
• W4289912917 hasLocation W42899129171 @default.
• W4289912917 hasLocation W42899129172 @default.
• W4289912917 hasOpenAccess W4289912917 @default.
• W4289912917 hasPrimaryLocation W42899129171 @default.
• W4289912917 hasRelatedWork W2037116344 @default.
• W4289912917 hasRelatedWork W2047967234 @default.
• W4289912917 hasRelatedWork W2061253854 @default.
• W4289912917 hasRelatedWork W2093554044 @default.
• W4289912917 hasRelatedWork W2362001173 @default.
• W4289912917 hasRelatedWork W2362661449 @default.
• W4289912917 hasRelatedWork W2439875401 @default.

• next